Molecular Analysis of Four Cases of Chronic Granulomatous Disease Caused by Defects in NCF-2: The Gene Encoding the p67-phox
Chronic granulomatous disease (CGD), a rare inherited primary immunodeficiency disorder, is caused by mutation in any one of the genes encoding components of nicotinamide adenine dinucleotide phosphate (NADPH)-oxidase enzyme. NCF2 gene (encoding P67-phox component) is one of them and its mutation is less common to cause CGD (around 5-6%). Here, we assessed mutation analysis of NCF2 in 4 CGD patients with p67-phox defect in Iran.
These patients showed classical CGD symptoms. NCF2 sequence analyses revealed two different homozygous mutations including a nonsense mutation in exon 4, c.304C>T (Arg102X) in one case and a CA deletion in exon 13 (Leu346fsX380) in one brother and sister;the latter is a new mutation which has not been reported in previous studies.
In another patient in whom the attempts to amplify exon 2 individually from genomic DNA were unsuccessful, PCR amplification of exon 2 revealed no band of this exon on agarose gel. A PCR amplification mix of exon 2 and exon 7, with an internal control, confirmed the lack of exon 2 in this patient. Although a gross deletion in other exons of NCF2 has been previously reported, a large deletion encompassing exon 2 has been not reported yet. This abstract was also presented in ESID 2012, Florence, Italy.
1. Segal BH, Leto TL, Gallin JI, Malech HL, Holland SM.Genetic, biochemical, and clinical features of chronic granulomatous disease. Medicine (Baltimore) 2000;79(3):170-200.
2. Matute JD, Arias AA, Wright NA, Wrobel I, Waterhouse CC, Li XJ, et al. A new genetic subgroup of chronic granulomatous disease with autosomal recessive mutations in p40 phox and selective defects in neutrophil NADPH oxidase activity. Blood 2009; 114(15):3309-15.
3. Cale CM, Jones AM, Goldblatt D. Follow up of patients with chronic granulomatous disease diagnosed since 1990. Clin Exp Immunol 2000; 120(2):351-5.
4. Jones LB, McGrogan P, Flood TJ, Gennery AR, Morton L, Thrasher A, et al. Special article: chronic granulomatous disease in the United Kingdom and Ireland: a comprehensive national patient-based registry. Clin Exp Immunol 2008; 152(2):211-8.
5. Liese J, Kloos S, Jendrossek V, Petropoulou T, Wintergerst U, Notheis G, et al. Long-term follow-up and outcome of 39 patients with chronic granulomatous disease. J Pediatr 2000; 137(5):687-93.
6. Martire B, Rondelli R, Soresina A, Pignata C, Broccoletti T, Finocchi A, et al. Clinical features, long-term follow- up and outcome of a large cohort of patients with Chronic Granulomatous Disease: an Italian multicenter study. Clin.Immunol 2008; 126(2):155-64.
7. van den Berg JM, van Koppen E, Ahlin A, Belohradsky BH, Bernatowska E, Corbeel L, et al. Chronic granulomatous disease: the European experience. PLoS One 2009; 4(4):e5234.
8. Ahlin A, De Boer M, Roos D, Leusen J, Smith CI, Sundin U et al. Prevalence, genetics and clinical presentation of chronic granulomatous disease in Sweden. Acta Paediatr 1995; 84(12):1386-94.
9. Winkelstein JA, Marino MC, Johnston RB Jr, Boyle J, Curnutte J, Gallin JI, et al. Chronic granulomatous disease. Report on a national registry of 368 patients. Medicine (Baltimore) 2000; 79(3):155-69.
10. Fattahi F, Badalzadeh M, Sedighipour L, Movahedi M,Fazlollahi MR, Mansouri SD, et al. Inheritance pattern and clinical aspects of 93 Iranian patients with chronic granulomatous disease. J Clin Immunol 2011; 31(5):792-801.
11. Köker MY, Sanal O, De Boer M, Tezcan I, Metin A, Ersoy F, et al. Mutations of chronic granulomatous disease in Turkish families. Eur J Clin Invest 2007;37(7):589-95.
12. Bakri FG, Martel C, Khuri-Bulos N, Mahafzah A, El- Khateeb MS, Al-Wahadneh AM, et al. First report of clinical, functional, and molecular investigation of chronic granulomatous disease in nine Jordanian families. J Clin Immunol 2009; 29(2):215-30.
13. Wolach B, Gavrieli R, de Boer M, Gottesman G, Ben-Ari J, Rottem M, et al. Chronic granulomatous disease in Israel: clinical, functional and molecular studies of 38 patients. Clin Immunol 2008; 129(1):103-14.
14. Vowells SJ, Fleisher TA, Sekhsaria S, Alling DW,Maguire TE, Malech HL. Genotype-dependent variability in flow cytometric evaluation of reduced nicotinamide adenine dinucleotide phosphate oxidase function in patients with chronic granulomatous disease. J Pediatr 1996; 128(1):104-7.
15 Kenney RT, Malech HL, Epstein ND, Roberts RL, Leto TL. Characterization of the p67phox gene: genomic organization and restriction fragment length polymorphism analysis for prenatal diagnosis in chronic granulomatous disease. Blood 1993; 82(12):3739-44.
16. Köker MY, Sanal O, van Leeuwen K, de Boer M, Metin A, Patiroğlu T, et al. Four different NCF2 mutations in six families from Turkey and an overview of NCF2 gene mutations. Eur J Clin Invest 2009; 39(10):942-51.
17. Patiño PJ, Rae J, Noack D, Erickson R, Ding J, de Olarte DG, et al. Molecular characterization of autosomal recessive chronic granulomatous disease caused by a defect of the nicotinamide adenine dinucleotide phosphate (reduced form) oxidase component p67-phox. Blood 1999; 94(7):2505-14.
18. Takeya R, Sumimoto H. Regulation of novel superoxide- producing NAD (P) H oxidases. Antioxid Redox Signal.2006; 8(9-10):1523-32
|Issue||Vol 11, No 4 (2012)|
|Chronic Granulomatous Disease P67-phox NADPH oxidase NCF2|
|Rights and permissions|
|This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.|